There are at least FIVE things that impact how you respond to taking Semaglutide or Wegovy and Ozempic - as they are commonly known, for weight loss. Today I look into what they are. The ultimate issue I discuss is why does a a 100 kilo woman and a 300 kilo man routinely both get perscribed the same dosing schedule and can we do it better?

Contact

investigatingozempic@gmail.com

Special Note

In this Podcast I am ONLY looking at the WEIGHT LOSS EFFECT of these GLP1 drugs and am not looking at the Diabetic effects. This podcast should not be construed as giving any type of medical advice. I am not a qualified health care professional.

Legal and Medical Disclaimer:

The Investigating Ozempic podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Every care has been taken to obtain accurate information including reaching out to Novo Nordisk for comment - which so far has remained unanswered. I encourage Novo Nordisk to contact me and correct any discrepancies that have been made accidentally and in good faith by the author. This podcast contains my personal opinion which is solely my own and not intended to be construed in any other manner.

Copyright

All rights reserved by Bernadette Fisers. Material in the podcast and any content therein is subject to copyright under Australian law and through international treaties, and applicable law in other countries.

Unless otherwise indicated, we (and/or our third-party licensors) own the copyright and other intellectual property rights in the recording, text, graphics, information, designs, data and other content in this document.

Links to Documents mentioned in the Podcast

Australian Public Assessment Report Wegovy

European Medicines Agency Assessment Report Semaglutide

European Medicines Agency Assessment Report Wegovy

FDA Centre for Drug Evaluation and Research Clinical Review

FDA Centre for Drug Evaluation and Research Summary Wegovy

Story Time 81 - The only good NFT is a No Frank Team